Meme Kanseri ve Fertilite

Anders, C.K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009). Breast cancer before age 40 years. Semin Oncol, 36, 237–249.

Hayat, M.J., Howlader, N., Reichman, M.E., & Edwards, B.K. (2007). Cancer statistics, trends, and multiple primary cancer analyses from the SEER Program. Oncologist, 12, 20–37.

Blakely, L.J., Buzdar, A.U., Lozada, J.A., Shullaih, S.A., Hoy, E., Smith, T.L., et al. (2004). Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer, 100, 465–469.

Mueller, B.A., Simon, M.S., Deapen, D., Kamineni, A., Malone, K.E., & Daling, J.R. (2003). Childbearing and survival after breast carcinoma in young women. Cancer, 98, 1131–1140.

Cvancarova, M., Samuelsen, S.O., Magelssen, H., & Fossa, S.D. (2009). Reproduction rates after cancer treatment: experience from the Norwegian radium hospital. J Clin Oncol, 27, 334–343.

Partridge, A.H., Gelber, S., Peppercorn, J., Sampson, E., Knudsen, K., Laufer, M., et al. (2004). Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol, 22, 4174–4183.

Velentgas, P., Daling, J.R., Malone, K.E., Weiss, N.S., Williams, M.A., Self, S.G., et al. (1999). Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer, 85, 2424–2432.

Largillier, R., Savignoni, A., Gligorov, J., Chollet, P., Guilhaume, M.N., Spielmann, M., et al. (2009). Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis. Cancer, 115, 5155–5165.

Ives, A., Saunders, C., Bulsara, M., & Semmens, J. (2007). Pregnancy after breast cancer: population based study. Br Med J, 334, 194.

Rosenberg, R., & Levy-Schwartz, R. (2003). Breast cancer in women younger than 40 years. Int J Fertil Womens Med, 48, 200–205.

Goldhirsch, A., Ingle, J.N., Gelber, R.D., Coates, A.S., Thurlimann, B., & Senn, H.J. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol, 20, 1319–1329.

Gnant, M., Greil, R., & Kubista, E. (2006). The impact of treatment-induced amenorrhea on survival of premenopausal patients with endocrine-responsive breast cancer: 10-year result of ABCSG-05 (CMF vs. goserelin + tamoxifen). Breast Cancer Res Treat, 100, S10–S11.

Vanhuyse, M., Fournier, C., & Bonneterre, J. (2005). Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol, 16, 1283–1288.

Colleoni, M., Gelber, S., Goldhirsch, A., Aebi, S., Castiglione-Gertsch, M., Price, K.N., et al. (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol, 24, 1332–1341.

Goel, S., Sharma, R., Hamilton, A., & Beith, J. (2009). LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev, 7(4), CD004562.

Petrek, J.A., Naughton, M.J., Case, L.D., Paskett, E.D., Naftalis, E.Z., Singletary, S.E., et al. (2006). Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol, 24, 1045–1051.

Walshe, J.M., Denduluri, N., & Swain, S.M. (2006). Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol, 24, 5769–5779.

Gerber, B., Dieterich, M., Muller, H., & Reimer, T. (2008). Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Res Treat, 108, 1–7.

Hickey, M., Peate, M., Saunders, C.M., & Friedlander, M. (2009). Breast cancer in young women and its impact on reproductive function. Hum Reprod Update, 15, 323–339.

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M.J. (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225–249.

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer Statistics, 2010. CA Cancer J Clin, 60, 277–300.

Ganz, P.A., Greendale, G.A., Petersen, L., Kahn, B., & Bower, J.E. (2003). Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol, 21, 4184–4193.

Phillips, K.A., Osborne, R.H., Giles, G.G., Dite, G.S., Apicella, C., Hopper, J.L., et al. (2008). Psychosocial factors and survival of young women with breast cancer: a population-based prospective cohort study. J Clin Oncol, 26, 4666–4671.

Gorman, J.R., Malcarne, V.L., Roesch, S.C., Madlensky, L., & Pierce, J.P. (2010). Depressive symptoms among young breast cancer survivors: the importance of reproductive concerns. Breast Cancer Res Treat, 123, 477–485.

Thewes, B., Butow, P., Girgis, A., & Pendlebury, S. (2004). The psychosocial needs of breast cancer survivors; a qualitative study of the shared and unique needs of younger versus older survivors. Psychooncology, 13, 177–189.

Kaufmann, M., Hortobagyi, G.N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., et al. (2006). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol, 24, 1940–1949.

Fredholm, H., Eaker, S., Frisell, J., Holmberg, L., Fredriksson, I., & Lindman, H. (2009). Breast cancer in young women: poor survival despite intensive treatment. PLoS One, 4, e7695.

Hartley, M.C., McKinley, B.P., Rogers, E.A., Kalbaugh, C.A., Messich, H.S., Blackhurst, D.W., et al. (2006). Differential expression of prognostic factors and effect on survival in young (≤40) breast cancer patients: a case-control study. Am Surg, 72, 1189–1194.

Meneses, K., McNees, P., Azuero, A., & Jukkala, A. (2010). Development of the Fertility and Cancer Project: an Internet approach to help young cancer survivors. Oncol Nurs Forum, 37, 191–197.

EBCTCG. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687–1717.

Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.

Hugh, J., Hanson, J., Cheang, M.C., Nielsen, T.O., Perou, C.M., Dumontet, C., et al. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol, 27, 1168–1176.

Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 351, 2817–2826.

Sparano, J.A., Wang, M., Martino, S., Jones, V., Perez, E.A., Saphner, T., et al. (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358, 1663–1671.

Parker, J.S., Mullins, M., Cheang, M.C., Leung, S., Voduc, D., Vickery, T., et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160–1167.

Albain, K.S., Paik, S., & van’t Veer, L. (2009). Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast, 18(Suppl 3), S141–S145.

Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659–1672.

Brewster, A.M., Hortobagyi, G.N., Broglio, K.R., Kau, S.W., Santa-Maria, C.A., Arun, B., et al. (2008). Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst, 100, 1179–1183.

Goss, P.E., Muss, H.B., Ingle, J.N., Whelan, T.J., & Wu, M. (2008). Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer, 8, 411–417.

Penault-Llorca, F., Andre, F., Sagan, C., Lacroix-Triki, M., Denoux, Y., Verriele, V., et al. (2009). Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol, 27, 2809–2815.

Bedard, P.L., Di Leo, A., & Piccart-Gebhart, M.J. (2010). Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol, 7, 22–36.

Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., et al. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 360, 679–691.

Goldhirsch, A., Gelber, R.D., & Castiglione, M. (1990). The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol, 1, 183–188.

Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995). Adjuvant CMF in node-positive breast cancer: 20-year follow-up. N Engl J Med, 332, 901–906.

Fisher, B., Brown, A.M., Dimitrov, N.V., Poisson, R., Redmond, C., Margolese, R.G., et al. (1990). Comparison of AC ± interval reinduction vs CMF in node-positive breast cancer with tamoxifen-nonresponsive tumors: NSABP B-15. J Clin Oncol, 8, 1483–1496.

Bines, J., Oleske, D.M., & Cobleigh, M.A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol, 14, 1718–1729.

Jones, S., Holmes, F.A., O’Shaughnessy, J., Blum, J.L., Vukelja, S.J., McIntyre, K.J., et al. (2009). Docetaxel with cyclophosphamide vs doxorubicin and cyclophosphamide: 7-year OS data from US Oncology 9735. J Clin Oncol, 27, 1177–1183.

Levine, M.N., Bramwell, V.H., Pritchard, K.I., Norris, B.D., Shepherd, L.E., Abu-Zahra, H., et al. (1998). Randomized trial of CEF vs CMF in premenopausal women with node-positive breast cancer. J Clin Oncol, 16, 2651–2658.

Hortobagyi, G.N., Buzdar, A.U., Marcus, C.E., & Smith, T.L. (1986). Toxicity of adjuvant chemotherapy regimens with doxorubicin at M.D. Anderson. NCI Monogr, 1, 105–109.

Swain, S.M., Land, S.R., Ritter, M.W., Costantino, J.P., Cecchini, R.S., Mamounas, E.P., et al. (2009). Amenorrhea in women on AC followed by docetaxel (NSABP B-30). Breast Cancer Res Treat, 113, 315–320.

Fornier, M.N., Modi, S., Panageas, K.S., Norton, L., & Hudis, C. (2005). Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer, 104, 1575–1579.

Tham, Y.L., Sexton, K., Weiss, H., Elledge, R., Friedman, L.C., & Kramer, R. (2007). The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol, 30, 126–132.

Perez-Fidalgo, J.A., Rosello, S., Garcia-Garre, E., Jorda, E., Martin-Martorell, P., Bermejo, B., et al. (2010). Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat, 120, 245–251.

Berliere, M., Dalenc, F., Malingret, N., Vindevogel, A., Piette, P., Roche, H., et al. (2008). Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer, 8, 56.

Slamon, D., & Pegram, M. (2001). Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol, 28, 13–19.

Costa, R.B., Kurra, G., Greenberg, L., & Geyer, C.E. (2010). Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol, 21, 2153–2160.

Ismail-Khan, R., & Bui, M.M. (2010). A review of triple-negative breast cancer. Cancer Control, 17, 173–176.

Rabban, J.T., Barnes, M., Chen, L.M., Powell, C.B., Crawford, B., & Zaloudek, C.J. (2009). Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations. Am J Surg Pathol, 33, 1125–1136.

Sanchez-Serrano, M., Novella-Maestre, E., Rosello-Sastre, E., Camarasa, N., Teruel, J., & Pellicer, A. (2009). Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod, 24, 2238–2243.

Badawy, A., Elnashar, A., El-Ashry, M., & Shahat, M. (2009). Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril, 91, 694–697.

Pereyra Pacheco, B., Mendez Ribas, J.M., Milone, G., Fernandez, I., Kvicala, R., Mila, T., et al. (2001). Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol, 81, 391–397.

Blumenfeld, Z., & Eckman, A. (2005). Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr, 2005, 40–43.

Dann, E.J., Epelbaum, R., Avivi, I., Ben Shahar, M., Haim, N., Rowe, J.M., et al. (2005). Fertility and ovarian function are preserved in women treated with intensified cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod, 20, 2247–2249.

Somers, E.C., Marder, W., Christman, G.M., Ognenovski, V., & McCune, W.J. (2005). Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum, 52, 2761–2767.

Castelo-Branco, C., Nomdedeu, B., Camus, A., Mercadal, S., Martinez de Osaba, M.J., & Balasch, J. (2007). Use of gonadotropin-releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function. Fertil Steril, 87, 702–705.

Blumenfeld, Z., Avivi, I., Eckman, A., Epelbaum, R., Rowe, J.M., & Dann, E.J. (2008). GnRH agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril, 89, 166–173.

Huser, M., Crha, I., Ventruba, P., Hudecek, R., Zakova, J., Smardova, L., et al. (2008). Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod, 23, 863–868.

Nitzschke, M., Raddatz, J., Bohlmann, M.K., Stute, P., Strowitzki, T., & von Wolff, M. (2009). GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients. Arch Gynecol Obstet, 282, 83–88.

Waxman, J.H., Ahmed, R., Smith, D., Wrigley, P.F., Gregory, W., Shalet, S., et al. (1987). Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol, 19, 159–162.

Giuseppe, L., Attilio, G., Edoardo, D.N., Loredana, G., Cristina, L., & Vincenzo, L. (2007). Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology, 12, 141–147.

Kim, S.S., Lee, J.R., Jee, B.C., Suh, C.S., Kim, S.H., Ting, A., Petroff, B. (2010). Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol, 53, 740–752.

Milliken, E.L., Lozada, K.L., Johnson, E., Landis, M.D., Seachrist, D.D., Whitten, I., et al. (2008). Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53. Oncogene, 27, 1759–1766.

Oktay, K., Buyuk, E., Libertella, N., Akar, M., Rosenwaks, Z. (2005). Fertility preservation in breast cancer patients: comparison of ovarian stimulation with tamoxifen and letrozole. J Clin Oncol, 23, 4347–4353.

Azim, A.A., Costantini-Ferrando, M., Oktay, K. (2008). Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in breast cancer patients. J Clin Oncol, 26, 2630–2635.

Chen, C. (1986). Pregnancy after human oocyte cryopreservation. Lancet, 1, 884–886.

Noyes, N., Porcu, E., Borini, A. (2009). Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online, 18, 769–776.

Grifo, J.A., Noyes, N. (2010). Delivery rate using cryopreserved oocytes is comparable to IVF with fresh oocytes: potential fertility preservation. Fertil Steril, 93, 391–396.

Nagy, Z.P., Chang, C.C., Shapiro, D.B., Bernal, D.P., Elsner, C.W., Mitchell-Leef, D., et al. (2009). Evaluation of efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril, 92, 520–526.

Noyes, N., Boldt, J., Nagy, Z.P. (2010). Oocyte cryopreservation: is it time to remove its experimental label? J Assist Reprod Genet, 27, 69–74.

Baka, S.G., Toth, T.L., Veeck, L.L., Jones, H.W., Muasher, S.J., Lanzendorf, S.E. (1995). Evaluation of the spindle apparatus of in-vitro matured human oocytes after cryopreservation. Hum Reprod, 10, 1816–1820.

Pickering, S.J., Braude, P.R., Johnson, M.H., Cant, A., Currie, J. (1990). Transient cooling to room temperature can cause irreversible disruption of the meiotic spindle in the human oocyte. Fertil Steril, 54, 102–108.

Kim, S.S. (2006). Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril, 85, 1–11.

Smith, G.D., Serafini, P.C., Fioravanti, J., Yadid, I., Coslovsky, M., Hassun, P., et al. (2010). Randomized comparison of oocyte cryopreservation with slow-rate freezing or vitrification. Fertil Steril, 94, 2088–2095.

Van Blerkom, J. (1989). Maturation of mouse oocytes after cryopreservation: alterations in structure associated with vitrification. Hum Reprod, 4, 883–898.

Newton, H., Aubard, Y., Rutherford, A., Sharma, V., Gosden, R. (1996). Low temperature storage and grafting of human ovarian tissue. Hum Reprod, 11, 1487–1491.

Donnez, J., Dolmans, M.M., Demylle, D., Jadoul, P., Pirard, C., Squifflet, J., et al. (2004). Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet, 364, 1405–1410.

Meirow, D., Levron, J., Eldar-Geva, T., Hardan, I., Fridman, E., Zalel, Y., et al. (2005). Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure. N Engl J Med, 353, 318–321.

Demeestere, I., Simon, P., Emiliani, S., Delbaere, A., Englert, Y. (2007). Successful transplantation of cryopreserved ovarian tissue in a young patient. Oncologist, 12, 1437–1442.

Andersen, C.Y., Rosendahl, M., Byskov, A.G., Loft, A., Ottosen, C., Dueholm, M., et al. (2008). Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod, 23, 2266–2272.

Roux, C., Amiot, C., Agnani, G., Aubard, Y., Rohrlich, P.S., Piver, P. (2010). Live birth after ovarian tissue autograft in sickle cell disease. Fertil Steril, 93(2413), e15–e19.

Sanchez-Serrano, M., Crespo, J., Mirabet, V., Cobo, A.C., Escriba, M.J., Simon, C., et al. (2009). Twins born after transplantation of ovarian tissue and oocyte vitrification. Fertil Steril, 30, 30.

Silber, S.J., DeRosa, M., Pineda, J., Lenahan, K., Grenia, D., Gorman, K., et al. (2008). Ovary transplantation (cortical vs microvascular) and cryopreservation in monozygotic twins. Hum Reprod, 23, 1531–1537.

von Wolff, M., Donnez, J., Hovatta, O., Keros, V., Maltaris, T., Montag, M., et al. (2009). Cryopreservation and autotransplantation of ovarian tissue prior to cytotoxic therapy. Eur J Cancer, 45, 1547–1553.

Perrotin, F., Marret, H., Bouquin, R., Fischer-Perrotin, N., Lansac, J., Body, G. (2001). Incidence, diagnosis and prognosis of ovarian metastasis in breast cancer. Gynecol Obstet Fertil, 29, 308–315.

Borst, M.J., Ingold, J.A. (1993). Metastatic patterns of invasive lobular vs ductal carcinoma of the breast. Surgery, 114, 637–641.

Kim, S.S., Battaglia, D.E., Soules, M.R. (2001). Future of ovarian cryopreservation and transplantation: fertility and beyond. Fertil Steril, 75, 1049–1056.

Demeestere, I., Simon, P., Emiliani, S., Delbaere, A., Englert, Y. (2009). Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update, 15, 649–665.

Oktay, K., Economos, K., Kan, M., Rucinski, J., Veeck, L., Rosenwaks, Z. (2001). Endocrine function and oocyte retrieval after transplantation of ovarian cortical strips to forearm. JAMA, 286, 1490–1493.

Kim, S.S., Hwang, I.T., Lee, H.C. (2004). Heterotopic autotransplantation of cryobanked ovarian tissue to restore function. Fertil Steril, 82, 930–932.

Kim, S.S., Lee, W.S., Chung, M.K., Lee, H.C., Lee, H.H., Hill, D. (2009). Long-term function and fertility after heterotopic autotransplantation of ovarian tissue. Fertil Steril, 91, 2349–2354.

Rosendahl, M., Loft, A., Byskov, A.G., Ziebe, S., Schmidt, K.T., Andersen, A.N., et al. (2006). Biochemical pregnancy after fertilization of oocyte from heterotopic autotransplant of ovarian tissue. Hum Reprod, 21, 2006–2009.

Oktay, K., Buyuk, E., Veeck, L., Zaninovic, N., Xu, K., Takeuchi, T., et al. (2004). Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet, 363, 837–840.